Industry News
Biotechnology Industry News

ProQR shares plummet as eye disease treatment flops phase 2/3 pediatric trial
ProQR shares plummet as eye disease treatment flops phase 2/3 pediatric trial mbayer Fri, 02/11/2022 - 10:47
Ex-FDA interim chief Giroir rejoins biotech world with eyes on $50M fundraising for new infectious disease company
Ex-FDA interim chief Giroir rejoins biotech world with eyes on $50M fundraising for new infectious disease company klahucik Fri, 02/11/2022 - 09:57
Cassava scores a win as FDA declines to intervene in petition to stop its Alzheimer’s drug trials
Cassava scores a win as FDA declines to intervene in petition to stop its Alzheimer's drug trials aarmstrong Fri, 02/11/2022 - 09:36
Metacrine lays off half its staff, mainly researchers, and ditches more work to focus on IBD after NASH disaster
Metacrine lays off half its staff, mainly researchers, and ditches more work to focus on IBD after NASH disaster klahucik Fri, 02/11/2022 - 09:27
Hunting for cutting-edge biotech, Fujifilm sets up early-stage VC fund
Hunting for cutting-edge biotech, Fujifilm sets up early-stage VC fund ntaylor Fri, 02/11/2022 - 05:43
With approval in sight, ObsEva sells regional rights to women’s health drug for tiny upfront
With approval in sight, ObsEva sells regional rights to women’s health drug for tiny upfront ntaylor Fri, 02/11/2022 - 04:50
Vivocore combines InterVivo, Transpharmation to form neuroscience CRO with an interest in psilocybin
Vivocore combines InterVivo, Transpharmation to form neuroscience CRO with an interest in psilocybin mbayer Thu, 02/10/2022 - 14:40
Curevo will go head-to-head against GSK’s Shingrix thanks to new $60M financing
Curevo will go head-to-head against GSK's Shingrix thanks to new $60M financing mbayer Thu, 02/10/2022 - 11:38
FDA denies Ardelyx’s appeal against kidney drug rejection, hammering another nail in tenapanor’s coffin
FDA denies Ardelyx’s appeal against kidney drug rejection, hammering another nail in tenapanor’s coffin ntaylor Thu, 02/10/2022 - 08:13
AstraZeneca dumps late-phase, next-gen COVID-19 vaccine, calling time on a beta player in an omicron world
AstraZeneca dumps late-phase, next-gen COVID-19 vaccine, calling time on a beta player in an omicron world ntaylor Thu, 02/10/2022 - 05:29
Indapta snags $50M financing and signs on former Juno exec as CEO
Indapta snags $50M financing and signs on former Juno exec as CEO mbayer Wed, 02/09/2022 - 14:51
Engineered TCR-T cells by Fred Hutch, San Raffaele-Intellia fend off evasive leukemia, solid tumors
Engineered TCR-T cells by Fred Hutch, San Raffaele-Intellia fend off evasive leukemia, solid tumors aliu Wed, 02/09/2022 - 11:41
Checkmate plucks BMS exec Bash to be new CEO
Checkmate plucks BMS exec Bash to be new CEO mbayer Wed, 02/09/2022 - 10:12
Rivus throws down mid-stage liver fat data on quest to climb NASH mountain
Rivus throws down mid-stage liver fat data on quest to climb NASH mountain aarmstrong Wed, 02/09/2022 - 09:36
Chasing Novartis and Roche, Ventus banks $140M to take inflammatory disease drug into the clinic
Chasing Novartis and Roche, Ventus banks $140M to take inflammatory disease drug into the clinic ntaylor Wed, 02/09/2022 - 08:14
GSK kills one of Barron’s early darlings, axing two synthetic lethal programs and Epizyme pact
GSK kills one of Barron’s early darlings, axing two synthetic lethal programs and Epizyme pact ntaylor Wed, 02/09/2022 - 06:17
GSK kills one of Barron’s early darlings, axing 2 synthetic lethal programs and Epizyme pact
GSK kills one of Barron's early darlings, axing 2 synthetic lethal programs and Epizyme pact ntaylor Wed, 02/09/2022 - 06:17
Chutes & Ladders—Editas fires chief medical officer without explanation
Chutes & Ladders—Editas fires chief medical officer without explanation admin Tue, 02/08/2022 - 17:11
Biotech IPOs in the current market environment? Experts say it’s ‘a bit silly, if not suicidal’
Biotech IPOs in the current market environment? Experts say it's 'a bit silly, if not suicidal' klahucik Tue, 02/08/2022 - 16:47
With $1.7T in the coffers, biopharma M&A expected to be ‘a different animal’ in 2022
With $1.7T in the coffers, biopharma M&A expected to be 'a different animal' in 2022 klahucik Tue, 02/08/2022 - 14:11

